Skip to main content

Table 2 Treatment-emergent adverse events reported by ≥5% of patientsa

From: Duloxetine in the treatment of major depressive disorder: an open-label study

 

n (%)

 

Duloxetine, 60 mg QD (N = 533)

Nausea

191 (35.8)

Headache

108 (20.3)

Dry mouth

96 (18.0)

Somnolence

72 (13.5)

Insomnia

56 (10.5)

Dizziness

54 (10.1)

Diarrhea

53 (9.9)

Constipation

42 (7.9)

Increased sweating

37 (6.9)

Anxiety

33 (6.2)

Decreased appetite

33 (6.2)

Tremor

32 (6.0)

Fatigue

31 (5.8)

Vomiting

28 (5.3)

  1. a Incidence is defined as the percentage of subjects reporting a first occurrence or worsening of the event during the acute phase of the study.
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us